The pre-metastatic niche: Finding common ground

Cancer and Metastasis Reviews

Volumn 32, Issue 3-4, 2013, Pages 449-464

  Sceneay, Jaclyn ^a,b,c   Smyth, Mark J ^a,b,c   Möller, Andreas ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Exosomes; Hypoxia; Immunosuppression; Myeloid derived suppressor cells; Pre metastatic niche; Tumor dormancy

Indexed keywords

CYTOKINE; GROWTH FACTOR;

BONE MARROW CELL; CYTOKINE RELEASE; EXOSOME; HUMAN; IMMUNOSURVEILLANCE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ANIMALS; ANOXIA; DISEASE PROGRESSION; EXOSOMES; HUMANS; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84890314061     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9420-1     Document Type: Review

References (109)

1. Gupta, G. P., & Massague, J. (2006). Cancer metastasis: building a framework. Cell, 127(4), 679-695.
2. Klein, C. A. (2008). Cancer. The metastasis cascade. Science, 321(5897), 1785-1787.
3. Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews. Cancer, 9(4), 239-252.
4. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674.
5. Paget, G. (1889). Remarks on a case of alternate partial anaesthesia. British Medical Journal, 1(1462), 1-3.
6. Muller, A., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50-56.
7. Weigelt, B., et al. (2005). No common denominator for breast cancer lymph node metastasis. British Journal of Cancer, 93(8), 924-932.
8. Kaplan, R. N., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820-827.
9. Psaila, B., & Lyden, D. (2009). The metastatic niche: adapting the foreign soil. Nature Reviews. Cancer, 9(4), 285-293.
10. Duda, D. G., & Jain, R. K. (2010). Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required? Cancer Research, 70(14), 5670-5673.
11. Dawson, M. R., et al. (2009). VEGFR1-activity-independent metastasis formation. Nature, 461(7262), E4. Discussion, E5.
12. Lin, E. Y., et al. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Research, 66(23), 11238-11246.
13. Nozawa, H., Chiu, C., & Hanahan, D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12493-12498.
14. Coussens, L. M., et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development, 13(11), 1382-1397.
15. Hiratsuka, S., et al. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nature Cell Biology, 8(12), 1369-1375.
16. Kowanetz, M., et al. (2010). Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G + Ly6C + granulocytes. Proceedings of the National Academy of Sciences of the United States of America, 107(50), 21248-21255.
17. Harris, A. L. (2002). Hypoxia - a key regulatory factor in tumour growth. Nature Reviews. Cancer, 2(1), 38-47.
18. Semenza, G. L. (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends in Pharmacological Sciences, 33(4), 207-214.
19. Bos, R., et al. (2003). Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer, 97(6), 1573-1581.
20. Dales, J. P., et al. (2005). Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. International Journal of Cancer, 116(5), 734-739.
21. Erler, J. T., et al. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell, 15(1), 35-44.
22. Wong, C. C., et al. (2011). Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proceedings of the National Academy of Sciences of the United States of America, 108(39), 16369-16374.
23. Bondareva, A., et al. (2009). The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. PLoS One, 4(5), e5620.
24. Sceneay, J., et al. (2012). Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Research, 72, 3906-11.
25. Chioda, M., et al. (2011). Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Reviews, 30(1), 27-43.
26. Yan, H. H., et al. (2010). Gr-1 + CD11b + myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Research, 70(15), 6139-6149.
27. Kim, S., et al. (2009). Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 457(7225), 102-106.
28. Granot, Z., et al. (2011). Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell, 20(3), 300-314.
29. Filipazzi, P., et al. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. Journal of Clinical Oncology, 25(18), 2546-2553.
30. Gabrilovich, D. I., & Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology, 9(3), 162-174.
31. Poschke, I., et al. (2010). Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Research, 70(11), 4335-4345.
32. Rodriguez, P. C., & Ochoa, A. C. (2006). T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Seminars in Cancer Biology, 16(1), 66-72.
33. Serafini, P., Borrello, I., & Bronte, V. (2006). Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology, 16(1), 53-65.
34. Youn, J. I., et al. (2008). Subsets of myeloid-derived suppressor cells in tumor-bearing mice. Journal of Immunology, 181(8), 5791-5802.
35. Almand, B., et al. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. Journal of Immunology, 166(1), 678-689.
36. Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12(4), 253-268.
37. Huang, B., et al. (2007). CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Letters, 252(1), 86-92.
38. Yang, L., et al. (2008). Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell, 13(1), 23-35.
39. Shojaei, F., et al. (2007). Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature, 450(7171), 825-831.
40. Sica, A., & Bronte, V. (2007). Altered macrophage differentiation and immune dysfunction in tumor development. The Journal of Clinical Investigation, 117(5), 1155-1166.
41. Gao, D., et al. (2012). Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Research, 72(6), 1384-1394.
42. Corzo, C. A., et al. (2010). HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. The Journal of Experimental Medicine, 207(11), 2439-2453.
43. Deng, J., et al. (2012). S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell, 21(5), 642-654.
44. Movahedi, K., et al. (2008). Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood, 111(8), 4233-4244.
45. Dolcetti, L., et al. (2010). Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. European Journal of Immunology, 40(1), 22-35.
46. Mauti, L. A., et al. (2011). Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. The Journal of Clinical Investigation, 121(7), 2794-2807.
47. Li, H., et al. (2009). Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. Journal of Immunology, 182(1), 240-249.
48. Hoechst, B., et al. (2009). Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology, 50(3), 799-807.
49. Zhu, J., Huang, X., & Yang, Y. (2012). Myeloid-derived suppressor cells regulate natural killer cell response to adenovirus-mediated gene transfer. Journal of Virology, 86, 13689-96.
50. Liu, C., et al. (2007). Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood, 109(10), 4336-4342.
51. Nagaraj, S., et al. (2012). Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Research, 72(4), 928-938.
52. Doedens, A. L., et al. (2010). Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Research, 70(19), 7465-7475.
53. Corzo, C. A., et al. (2010). HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. The Journal of Experimental Medicine, 207(11), 2439-2453.
54. Gallina, G., et al. (2006). Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. The Journal of Clinical Investigation, 116(10), 2777-2790.
55. Watanabe, S., et al. (2008). Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. Journal of Immunology, 181(5), 3291-3300.
56. Nagaraj, S., et al. (2007). Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nature Medicine, 13(7), 828-835.
57. Serafini, P., et al. (2008). Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Research, 68(13), 5439-5449.
58. Huang, B., et al. (2006). Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research, 66(2), 1123-1131.
59. Pan, P. Y., et al. (2010). Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Research, 70(1), 99-108.
60. Paez, D., et al. (2012). Cancer dormancy: a model of early dissemination and late cancer recurrence. Clinical Cancer Research, 18(3), 645-653.
61. Pavlidis, N., & Pentheroudakis, G. (2012). Cancer of unknown primary site. Lancet, 379(9824), 1428-1435.
62. Uhr, J. W., & Pantel, K. (2011). Controversies in clinical cancer dormancy. Proceedings of the National Academy of Sciences of the United States of America, 108(30), 12396-12400.
63. Almog, N. (2010). Molecular mechanisms underlying tumor dormancy. Cancer Letters, 294(2), 139-146.
64. Ringel, M. D. (2011). Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid, 21(5), 487-492.
65. Chaput, N., & Thery, C. (2011). Exosomes: immune properties and potential clinical implementations. Seminars in Immunopathology, 33(5), 419-440.
66. Ratajczak, J., et al. (2006). Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia, 20(9), 1487-1495.
67. Peinado, H., Lavotshkin, S., & Lyden, D. (2011). The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Seminars in Cancer Biology, 21(2), 139-146.
68. Peinado, H., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18, 883-91.
69. Jung, T., et al. (2009). CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia, 11(10), 1093-1105.
70. Grange, C., et al. (2011). Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Research, 71(15), 5346-5356.
71. Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Reviews Immunology, 4(12), 941-952.
72. Do, T. H., et al. (2004). Impaired circulating myeloid DCs from myeloma patients. Cytotherapy, 6(3), 196-203.
73. Liu, C., et al. (2006). Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. Journal of Immunology, 176(3), 1375-1385.
74. Huber, V., et al. (2005). Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology, 128(7), 1796-1804.
75. Valenti, R., et al. (2006). Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Research, 66(18), 9290-9298.
76. Xiang, X., et al. (2009). Induction of myeloid-derived suppressor cells by tumor exosomes. International Journal of Cancer, 124(11), 2621-2633.
77. Liu, Y., et al. (2010). Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. The American Journal of Pathology, 176(5), 2490-2499.
78. Yu, S., et al. (2007). Tumor exosomes inhibit differentiation of bone marrow dendritic cells. Journal of Immunology, 178(11), 6867-6875.
79. Park, J. E., et al. (2010). Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Molecular & Cellular Proteomics, 9(6), 1085-1099.
80. Wong, C. C., et al. (2012). Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. Journal of Molecular Medicine (Berlin), 90, 803-15.
81. Hiratsuka, S., et al. (2008). The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nature Cell Biology, 10(11), 1349-1355.
82. Skog, J., et al. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology, 10(12), 1470-1476.
83. Noerholm, M., et al. (2012). RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer, 12, 22.
84. Khan, S., et al. (2012). Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLoS One, 7(10), e46737.
85. Chen, T., et al. (2011). Chemokine-containing exosomes are released from heat-stressed tumor cells via lipid raft-dependent pathway and act as efficient tumor vaccine. Journal of Immunology, 186(4), 2219-2228.
86. Levy, E. M., Roberti, M. P., & Mordoh, J. (2011). Natural killer cells in human cancer: from biological functions to clinical applications. Journal of Biomedicine and Biotechnology, 2011, 676198.
87. Jinushi, M., et al. (2008). MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 105(4), 1285-1290.
88. Sibbitt, W. L., Jr., et al. (1984). Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma. Cancer Research, 44(2), 852-856.
89. Konjevic, G., et al. (2009). Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers, 14(4), 258-270.
90. Konjevic, G., et al. (2007). Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clinical & Experimental Metastasis, 24(1), 1-11.
91. Gill, S., Olson, J. A., & Negrin, R. S. (2009). Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biology of Blood and Marrow Transplantation, 15(7), 765-776.
92. Burke, S., et al. (2010). New views on natural killer cell-based immunotherapy for melanoma treatment. Trends in Immunology, 31(9), 339-345.
93. Koehn, T. A., et al. (2012). Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Frontiers in Pharmacology, 3, 91.
94. Sawanobori, Y., et al. (2008). Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood, 111(12), 5457-5466.
95. Shojaei, F., et al. (2009). G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proceedings of the National Academy of Sciences, 106(16), 6742-6747.
96. Mazzoni, A., et al. (2002). Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. The Journal of Immunology, 168(2), 689-695.
97. Yang, L., et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409-421.
98. Melani, C., et al. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Research, 67(23), 11438-11446.
99. Sinha, P., et al. (2008). Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. The Journal of Immunology, 181(7), 4666-4675.
100. Cheng, P., et al. (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. The Journal of Experimental Medicine, 205(10), 2235-2249.
101. Terabe, M., et al. (2003). Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance. The Journal of Experimental Medicine, 198(11), 1741-1752.
102. Xiang, X., et al. (2009). Induction of myeloid-derived suppressor cells by tumor exosomes. International Journal of Cancer, 124(11), 2621-2633.
103. Gabrilovich, D., et al. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92(11), 4150-4166.
104. Kusmartsev, S., et al. (2008). Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. Journal of Immunology, 181(1), 346-353.
105. Shojaei, F., et al. (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnology, 25(8), 911-920.
106. van Cruijsen, H., et al. (2007). Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clinical & Developmental Immunology, 2007, 17315-17315.
107. Hiratsuka, S., et al. (2011). Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proceedings of the National Academy of Sciences of the United States of America, 108(9), 3725-3730.
108. Schelter, F., et al. (2011). Tissue inhibitor of metalloproteinases-1- induced scattered liver metastasis is mediated by hypoxia-inducible factor-1alpha. Clinical & Experimental Metastasis, 28(2), 91-99.
109. Gil-Bernabé, A. M., et al. (2012). Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood, 119, 3164-75.